【摘要】 目的比较和评价含莫西沙星(MXFX)方案与含左氧氟沙星(LVFX)方案联合母牛分枝杆菌菌苗(M.vaccae)对耐多药肺结核病(MDR-PTB)的治疗效果及安全性。方法将78例痰菌阳性的MDR-PTB患者随机分成试验组(T组)与对照组(C组)每组39例,T组方案:6MDEZA(C)/12MDE、6MDEBTh/12MDE;C组方案:6VDEZA(C)/12MDE、6VDEBTh/12MDE方案。2组患者于治疗期间前6个月均加用M.vaccae,疗程结束时可评价疗效者T组33例、C组30例。结果治疗满2个月时痰菌阴转率T组为45.45%、C组为20.00%(P<0.05);治疗满4个月时痰菌阴转率T组为57.57%、C组为30.00%(P<0.05);以后各期痰菌阴转率T组均大于C组,但差异无统计学意义(P>0.05);满疗程时2组病灶吸收好转率分别为66.67%、46.67%,空洞闭合率为分别为17.24%、12.00%,2组比较差异无统计学意义(P>0.05)。不良反应:T组为30.76%(12/39),C组为38.46%(15/39),差异无统计学意义(P>0.05)。结论莫西沙星对MDR-PTB的治疗是有效且安全的。更多还原

【Abstract】 Objective To compare and evaluate the therapeutic effect and safety of moxifloxacin-containing protocol and levofloxicin-containing protocol in patients with multiple-drug resistant pulmonary tuberculosis(MDR-PTB).Methods 70 patients with MDR-PTB whose sputum cultures were positive were randomly divided into trial group(n=39)and control group(n=39).The treatment protocol of trial group was 6MDEZA(C)/12MDE,6MDEBTh/12MDE,however,which in control group was 6VDEZA(C)/12MDE,6DVEBTh/12MDE.The patients in both groups were administrated with M.vaccae in the initial 6 months.The therapeutic effects were evaluated at the end of treatment course for 33 patients in trial group and 30 patients in control group.Results At the end of 2 months after treatment,the sputum negative conversion rate in trial group was 45.45%,however,which in control group was 20.00%,there was a significant difference between two groups(P<0.05);at the end of 4 months after treatment,the sputum negative conversion rate in trial group was 57.57%,however,which in control group was 30.00%,there was a significant difference between two groups(P<0.05).The sputum negative conversion rates in trial group at latter periods were higher than those in control group,but there was no significant difference between two groups(P>0.05).At the end of treatment course,the focus absorption improvement rates in trial group and control group were 66.67%,46.67%,respectively,cavity closing rates were 17.24%,12.00%,respectively,and there were no significant differences between two groups(P>0.05).The incidence of adverse reaction:it in trial group was 30.76%(12/39),and it in control group was 38.46%(15/39),and there were no significant differences between two groups(P>0.05).Conclusion The moxiflocacin is effective and safe in the treatment of MDR-PTB.更多还原